Work

Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

Year: 2019

Type: article

Abstract: mRNA, were minimally affected by AVPR1A depletion. Ectopic expression of AVPR1A in androgen-dependent PC cells conferred castration resistance in vitro and in vivo. Furthermore, treatment of CRPC cells with the AVPR1A ligand, arginine vasopressin (AVP), activated ERK and CREB, known promoters of PC progression. A clinically safe and selective AVPR1A antagonist, relcovaptan, prevented CRPC emergence and decreased CRPC orthotopic and bone metastatic growth in mouse models. Based on these preclinical findings, repurposing AVPR1A antagonists is a promising therapeutic approach for CRPC.

Source: Science Translational Medicine

DOI: 10.1126/scitranslmed.aaw4636

Authors: Ning Zhao, Stephanie O. Peacock, Chen Hao Lo, Laine M. Heidman, Meghan A. Rice, Cale D. Fahrenholtz, Ann M. Greene, Fiorella Magani, Valeria A. Copello, Maria Julia Martinez, Yushan Zhang, Yehia Daaka, Conor C. Lynch, Kerry L. Burnstein

Institutions: University of Miami, Sylvester Comprehensive Cancer Center, Moffitt Cancer Center, University of Florida

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Wallace H. Coulter Foundation, Florida Academic Cancer Center Alliance, National Institute on Aging, National Cancer Institute

Awards: G2251775418, REPURPOSING DRUGS FOR PROSTATE CANCER THERAPY, Regulation of androgen receptor activity in prostate cancer cells in an aged mous, MICRORNA REGULATION OF VAV3, A NOVEL ANDROGEN RECEPTOR COACTIVATOR IN PROSTATE CANCER PROGRESSION, Moffitt Cancer Center Support Grant

OpenAlex ID: W2955123485

FWCI: 7.17

Cites: 58

Cited by: 64

Related to: 10